Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 19/20 | 0.63 |
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.54 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29509772 | 0.89 | MGLL (0.61) | MGLLPLA2G7ABHD6 | |
| SCHEMBL19992914 | 0.89 | MGLL (0.61) | MGLLPLA2G7ABHD6 | |
| SCHEMBL19992936 | 0.83 | MGLL (0.76) | MGLLPLA2G7ABHD6 | |
| SCHEMBL19992938 | 0.83 | MGLL (0.61) | MGLLPLA2G7ABHD6 | |
| SCHEMBL18087124 | 0.83 | MGLL (0.65) | MGLLPLA2G7ABHD6 | |
| SCHEMBL19992935 | 0.82 | MGLL (0.60) | MGLLPLA2G7ABHD6 | |
| SCHEMBL19992934 | 0.81 | MGLL (0.79) | MGLLPLA2G7ABHD6 | |
| SCHEMBL18087145 | 0.81 | MGLL (0.56) | MGLLPLA2G7ABHD6 | |
| SCHEMBL18064772 | 0.80 | MGLL (0.80) | MGLLPLA2G7ABHD6 | |
| SCHEMBL18087131 | 0.79 | MGLL (0.67) | MGLLPLA2G7ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| EP-3515897-B1 | PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE | H LUNDBECK AS (DK) | 2021-08-18 | — | — | EP | disclosed |
| EP-3515897-B1 | PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE | H LUNDBECK AS (DK) | 2021-08-18 | — | — | EP | disclosed |
| US-10899737-B2 | Piperazine carbamates and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| WO-2020154683-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-07-04 | — | — | US | disclosed |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-07-04 | — | — | US | disclosed |
| WO-2018053447-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899737-B2 | Piperazine carbamates and methods of making and using same | ABHD6, RABL6, ABHD16A | MGLL 46/4885PLA2G7 204/4885ABHD6 1/4885 |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | MGLL, LIPA, PNLIP | MGLL 1/4885PLA2G7 141/4885ABHD6 49/4885 |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABHD6, RABL6, ABHD16A | MGLL 46/4885PLA2G7 204/4885ABHD6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.